NEW TREATMENT MODALITIES IN OSTEOPOROSIS

被引:24
作者
Canalis, Ernesto [1 ]
机构
[1] Univ Connecticut, Sch Med, Farmington, CT USA
关键词
BONE-MINERAL DENSITY; GROWTH-FACTOR-I; CATHEPSIN-K; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; TARGETED DISRUPTION; STRONTIUM RANELATE; VERTEBRAL FRACTURE; DOUBLE-BLIND; SRC KINASE;
D O I
10.4158/EP10048.RA
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe recently discovered agents for the management of osteoporosis. Methods: A literature review (PubMed search) was conducted to identify agents at various stages of development for osteoporosis treatment. Agents under study or review for approval were included. Results: In menopause, bone remodeling is increased, and agents that suppress bone resorption can stabilize bone mass. In contrast, agents that target the osteoblast can increase bone formation and bone mass. Novel antiresorptive agents can target the formation or the activity of osteoclasts. They include denosumab, an antibody to receptor activated nuclear factor kappa B; new selective estrogen receptor modulators, such as bazedoxifene; and cathepsin K inhibitors, such as odanacatib. Src kinase inhibitors are in the early phases of development. Parathyroid hormone is the only approved anabolic agent for the treatment of osteoporosis. Novel anabolic therapies for osteoporosis may include the use of factors with anabolic properties for bone or the neutralization of growth factor antagonists. Recent discoveries have demonstrated that the Wnt/beta-catenin signaling pathway has a central role in osteoblastic cell differentiation. Antibodies to Wnt antagonists, such as sclerostin, are under development as new therapeutic approaches for osteoporosis. Anabolic therapies have the potential to enhance bone mass, but their long-term safety must be proven. Conclusions: New developments in the treatment of osteoporosis include novel antiresorptive and anabolic agents. Their success will depend on their long-term effectiveness and safety profile. (Endocr Pract. 2010;16:855-863)
引用
收藏
页码:855 / 863
页数:9
相关论文
共 68 条
[1]   Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women [J].
Archer, David F. ;
Pinkerton, JoAnn V. ;
Utian, Wulf H. ;
Menegoci, Jose C. ;
de Villiers, Tobie J. ;
Yuen, Chui Kin ;
Levine, Amy B. ;
Chines, Arkadi A. ;
Constantine, Ginger D. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (06) :1109-1115
[2]   Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J].
Balemans, W ;
Ebeling, M ;
Patel, N ;
Van Hul, E ;
Olson, P ;
Dioszegi, M ;
Lacza, C ;
Wuyts, W ;
Van den Ende, J ;
Willems, P ;
Paes-Alves, AF ;
Hill, S ;
Bueno, M ;
Ramos, FJ ;
Tacconi, P ;
Dikkers, FG ;
Stratakis, C ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
HUMAN MOLECULAR GENETICS, 2001, 10 (05) :537-543
[3]  
BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI [DOI 10.1056/NEJMOA067312, 10.1056/NEJMoa067312]
[4]   A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation [J].
Bodine, Peter V. N. ;
Stauffer, Barbara ;
Ponce-de-Leon, Helga ;
Bhat, Ramesh A. ;
Mangine, Annamarie ;
Seestaller-Wehr, Laura M. ;
Moran, Robert A. ;
Billiard, Julia ;
Fukayama, Shoichi ;
Komm, Barry S. ;
Pitts, Keith ;
Krishnamurthy, Girija ;
Gopalsamy, Ariamala ;
Shi, Mengxiao ;
Kern, Jeffrey C. ;
Commons, Thomas J. ;
Woodworth, Richard P. ;
Wilson, Matthew A. ;
Welmaker, Gregory S. ;
Trybulski, Eugene J. ;
Moore, William J. .
BONE, 2009, 44 (06) :1063-1068
[5]   Effects of denosumab on bone mineral density and bone turnover in postmenopausal women [J].
Bone, Henry G. ;
Bolognese, Michael A. ;
Yuen, Chui Kin ;
Kendler, David L. ;
Wang, Huei ;
Liu, Yu ;
Martin, Javier San .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2149-2157
[6]   Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].
Bone, Henry G. ;
McClung, Michael R. ;
Roux, Christian ;
Recker, Robert R. ;
Eisman, John A. ;
Verbruggen, Nadia ;
Hustad, Carolyn M. ;
DaSilva, Carolyn ;
Santora, Arthur C. ;
Ince, B. Avery .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947
[7]  
Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661 , 10.1517/13543780902832661]
[8]  
Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]
[9]  
Bühling F, 1999, AM J RESP CELL MOL, V20, P612
[10]   The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro [J].
Canalis, E ;
Hott, M ;
Deloffre, P ;
Tsouderos, Y ;
Marie, PJ .
BONE, 1996, 18 (06) :517-523